Search Results

Xylyx Bio today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor organs to transplant condition.

Next Gen Diagnostics and a team at Vanderbilt University Medical Center announced the results of a study reporting that comparison of the whole genome sequence of bacterial pathogens obtained from surveillance of infants in a neonatal intensive care unit revealed substantial transmission of infection not detected by conventional infection control procedures.

Royal Philips, a global leader in health technology, and Vanderbilt University Medical Center, home to the top-ranked adult and pediatric hospitals in the Southeastern U.S., announced a collaboration that aims to reduce the health system’s carbon footprint while determining a blueprint to guide industry efforts.

The CIRCLES Consortium, consisting of Vanderbilt University, UC Berkeley, Temple University and Rutgers University-Camden, in coordination with Nissan North America and Tennessee Department of Transportation, concluded a five-day open-track experiment on Nov. 18.

Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”) today announced that it has acquired an exclusive license from Vanderbilt University for a U.S. patent related to methods for predicting patient response to immunotherapies in cancers, US 10,969,392, expanding the Company’s patent portfolio to 10.

T2 Biosystems, Inc. (NASDAQ:TTOO) today announced a collaborative relationship with Vanderbilt University Medical Center’s (VUMC) Learning Healthcare System (LHS) Platform, which unites clinical research and clinical operations to evaluate and implement new approaches to care that can improve the health of patients and the community.

Revelation Biosciences Inc. today announced an exclusive worldwide license agreement with Vanderbilt University, Nashville TN, USA (Vanderbilt) to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD), for treating or preventing infections.

Lobe Sciences Ltd. today announced that Dr. Harry Jacobson has agreed to join its Board of Directors.